ORAL ABSTRACT: AML-789 Ziftomenib in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia (AML): Phase 1b/2 Results From the Pivotal KOMET-001 Study
Year: 2025
Type: article
Authors: Ghayas C. Issa, Eunice S. Wang, Pau Montesinos, James Foran, Harry Erba, Eduardo Rodríguez-Arbolí, Kateryna Fedorov, Maël Heiblig, Florian H. Heidel, Jessica K. Altman, Maria R. Baer, Lionel Ades, Kristen Pettit, Pierre Peterlin, Cristina Papayannidis, Zijing Zhang, Marcie Riches, Daniel Corum, Mollie Leoni, Amir T. Fathi
Institutions: The University of Texas MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, Hospital Universitari i Politècnic La Fe, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Florida), Duke University, Duke Cancer Institute, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Hôpital Lyon Sud, Medizinische Hochschule Hannover, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Hôpital Saint-Louis, University of Michigan, Centre Hospitalier Universitaire de Nantes, Istituto di Ematologia di Bologna, Kura Oncology (United States), Harvard University, Massachusetts General Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413781417